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The value of the squeeze test for detection of
subclinical synovitis in patients with arthralgia
suspicious for progression to RA
Rheumatology key message
. A positive squeeze test in clinically suspect arthral-
gia is associated with presence of subclinical
synovitis.
SIR, The squeeze test (or compression test) is often used
to quickly screen for arthritis in MCP and MTP joints. A
positive test is traditionally assumed to indicate presence
of synovitis [1]. Previous studies in early arthritis indeed
showed that a positive squeeze test was associated with
presence of swollen MCP and MTP joints, as well as with
local MRI-detected inflammation [2]. The sensitivity of the
test, with MRI-detected synovitis as reference, was
3133% [2]. The field of early arthritis is moving towards
identifying patients at risk for RA in the phase of arthralgia.
MRI-detected subclinical inflammation has been shown to
be predictive for RA development; of all inflammatory fea-
tures, tenosynovitis had the strongest association [3]. We
here aimed to assess if a positive squeeze test in patients
with clinically suspect arthralgia (CSA) is associated with
subclinical inflammation. We specifically hypothesized
that it is associated with subclinical synovitis, in line with
the original assumption of the test being a measure of
synovitis. MRI-detected tenosynovitis was also studied,
because we assumed that tenosynovitis at MCP or MTP
level may also produce pain upon compression. Finally,
we studied the association of the test with progression to
inflammatory arthritis (IA).
Between April 2015 and October 2018, 315 patients
were consecutively included in the Leiden CSA cohort;
details are provided in the Supplementary material, sec-
tion ‘Methods’, available at Rheumatology online.
Inclusion criteria were recent-onset (<1 year) arthralgia
of small joints and a clinical suspicion for progression to
RA, which means that according to the pattern recognition
of the rheumatologist at first visit, imminent RA was more
likely than other diagnoses, as described previously [4]. All
patients gave written informed consent. The study was
approved by the local medical ethical committee. At base-
line the squeeze test was performed; compression across
the knuckles of MCP and MTP joints with the force of a
firm handshake, as described previously [2]. Unilateral
contrast-enhanced 1.5 T MRI of MCP (25) and MTP
(15) joints was also made at baseline and scored by
two trained readers for synovitis (according to RAMRIS
[5]) and tenosynovitis (according to Haavardsholm et al.
[6]). MRI scores were dichotomized with data from age-
matched symptom-free controls as reference. A detailed
scanning and scoring protocol and information on dichot-
omization is provided in the Supplementary material, sec-
tion ‘Methods’, available at Rheumatology online. Follow-
up ended when patients developed clinically apparent IA
(determined at physical examination), or else after 2 years.
Associations of the squeeze test and MRI data (data of
same extremity at baseline) were studied with generalized
estimating equations, to account for the fact that in every
patient a hand and a foot was assessed. The association
of the squeeze test with IA development was determined
using Cox regression.
Flowchart and baseline characteristics are shown in the
Supplementary material (Supplementary Fig. S1 and
Supplementary Table S1, available at Rheumatology
online). Fifty-one per cent of CSA patients had a positive
squeeze test in MCP or MTP joints. In univariable analyses
a positive test was associated with local subclinical syno-
vitis [odds ratio (OR) 2.10 (95% CI 1.303.40), Fig. 1A]
and tenosynovitis [OR 1.68 (95% CI 1.052.68);
Supplementary Table S2, available at Rheumatology
online]. In multivariable analyses including both inflamma-
tory features only synovitis remained significant [OR 1.90
(95% CI 1.163.13), Fig. 1A], also after further correction
for age and gender (Fig. 1A, Supplementary Table S2,
available at Rheumatology online). Thus, a positive
squeeze test is a measure of subclinical synovitis, with a
sensitivity of 44% (95% CI 3355%) and specificity of
72% (95% CI 6876%). When analysing MCP and MTP
joints separately, the squeeze test was also associated
with subclinical synovitis [OR 2.08 (95% CI 1.024.22)
and 2.13 (95% CI 1.104.12), respectively, in univariable
analyses; Fig. 1B and C, Supplementary Table S2, avail-
able at Rheumatology online].
A positive squeeze test in patients with CSA was not
associated with IA development in Cox regression
adjusted for age, gender, CRP and ACPA-status [hazard
ratio (HR) 1.57 (95% CI 0.773.19); Supplementary Table
S3, available at Rheumatology online]. This is consistent
with the finding that subclinical synovitis was not asso-
ciated with IA development in multivariable analysis
adjusted for age, gender, CRP, ACPA status and subcli-
nical tenosynovitis [HR 1.40 (95% CI 0.593.31)], whilst
tenosynovitis was associated [HR 4.94 (95% CI
2.0312.06); Supplementary Table S4, available at
Rheumatology online].
The squeeze test is known for its association with syno-
vitis in patients with clinically manifest arthritis. This study
is the first to investigate the association with subclinical
inflammation in the phase of CSA. We demonstrated that
a positive test was indeed associated with presence of
subclinical synovitis. The sensitivity was 44%; this indi-
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the squeeze test. For certainty on presence of subclinical
synovitis imaging could be used. However, whilst MRI is
more sensitive for detection of subclinical synovitis, it is
also invasive and costly. In contrast, the squeeze test is
easy to perform and free of costs, and therefore it can
provide value as a first screening tool.
The squeeze test of the MCPs is, in combination with
other clinical characteristics, part of the EULAR definition
of arthralgia suspicious for progression to RA. This defini-
tion serves to identify this group of arthralgia patients and
to distinguish them from arthralgia with other causes
[7, 8].
A positive squeeze test within CSA was not significantly
associated with IA development. This may seem counter-
intuitive, as we have shown that it is a test for subclinical
synovitis and subclinical inflammation is predictive for IA.
However, this is explained by the fact that the latter asso-
ciation is mainly driven by tenosynovitis, as was shown
previously [3]. Also in current data synovitis was not sig-
nificantly associated with IA development, in contrast to
tenosynovitis.
In sum, the squeeze test is a simple test that, when
positive in CSA, doubles the probability of presence of
subclinical synovitis.
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The effect of reducing systemic inflammation on
serum urate
Rheumatology key message
. Decreasing systemic inflammation leads to an
increase in serum urate.
SIR, urate is a product of the metabolic breakdown of
purine nucleotides, and raised serum urate (hyperuri-
caemia) is the primary cause of the inflammatory arthritis
gout. During gout flares it is well established that serum
urate (SU) concentrations decrease and up to 49% of
patients have levels within normal reference ranges [1, 2].
This has been hypothesized to be related to the systemic
inflammatory response rather than the gout disease pro-
cess itself. Waldron and colleagues demonstrated a signif-
icant reduction in SU when patients without gout had major
surgery [3]. This leads to the consideration of the inverse
situation when systemic inflammation is suppressed. It is
therefore of interest to assess how SU may be affected by
a significant reduction in inflammation, as occurs in
patients with active rheumatic disease who commence
potent immunosuppressants.
An analysis was performed using a database of adult
patients from a rheumatology service who had been com-
menced on a biologic disease modifying anti-rheumatic
drug (bDMARD). Included patients were started on the
bDMARD while known to the clinic and completed at
least 3 months of uninterrupted therapy. There were no
patients with gout in the cohort. SU, at least one of inflam-
matory markers CRP or ESR, and renal function results
were required to be available from within 3 months prior
to, and 36 months after, commencement of the
bDMARD. Exclusion criteria included inadequate records
of commencement, no SU or inflammatory markers avail-
able within the specified time frames, or intercurrent ill-
ness at the time of specimen collection. Paired t test
analysis was performed comparing SU, inflammatory mar-
kers, and renal function before and after initiation of the
bDMARD. Ethics approval was granted by the local insti-
tutional ethics committee (the Royal Brisbane & Women’s
Hospital Human Research Ethics Committee; HREC/
2018/QRBW/45944).
Records of 289 patients were examined, with 108 of
these meeting inclusion criteria; 63% of the patients were
female, and the median age of participants was 54.5 years
(IQR 4261 years). The indication for bDMARD use was RA
(63%), psoriatic arthritis (24.1%) ankylosing spondylitis
(12%) and other inflammatory disease (0.9%). The
bDMARDs used were predominantly tumour necrosis
factor inhibitors (85%) with a small number of patients
receiving one of five other bDMARDs.
After commencement of bDMARD therapy, mean SU
increased from 0.286 to 0.305 mmol/l; see Table 1. CRP
and ESR were also significantly reduced and renal func-
tion was unchanged. These results provide evidence that
SU significantly increases following commencement of
potent immunosuppression. In this cohort we have also
provided evidence of a coincident significant reduction in
CRP and ESR supporting the assertion of a reduction in
systemic inflammation. Taken together with the observa-
tion of decreases in SU in gout flare and in elective sur-
gery, this supports a two-way relationship between the
level of systemic inflammation and SU. The mechanism
behind this relationship remains unclear, but may be
related to changes in the fractional excretion of urate pos-
sibly precipitated by an alteration in the inflammatory
milieu [1, 4].
The increase in SU with immunosuppression could also
contribute to the coexistence of hyperuricaemia or gout in
patients with systemic inflammatory disorders who receive
effective therapies. A large recently reported cohort of RA
patients (n = 1999) had a 6.1% prevalence of co-existent
gout, higher than expected from the general population
[5, 6]. Whilst decreases in SU during gout flare have been
long observed, this is the first demonstration that the phe-
nomenon also occurs in reverse. Future work could focus
on demonstrating a possible difference in fractional
TABLE 1 Laboratory results prior to and after commencing biologic disease modifying anti-rheumatic drugs
n Prior Post P
Serum urate (0.12 - 0.45 mmol/l) 108 0.286 0.305 0.00025
CRP (<5 mg/l) 108 24.8 10.2 <0.00001
Erythrocyte sedimentation rate (1 - 20 mm/h) 100 34.7 19.4 <0.00001
eGFR (>90 ml/min/1.73 m2) 108 84.8 84.0 0.23
eGFR: estimated glomerular filtration rate.
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